The aim of this study is to investigate the usability of the Turkish version of the Keel Start Tool as a valid and reliable method in groups with 5 different types of musculoskeletal pain (knee, neck, shoulder, back, multiple painful areas). When the literature is examined, Turkish validity has not been made in this area.

SK diseases are the 3 most common disease groups in Turkey, and it has been determined that the rate of discomfort in Turkey is 99%. Although MSK diseases are mostly caused by occupational problems in Turkey, there are clearly information losses and deficiencies in cases such as the risk factors of employers and employees, occupational therapy, lack of insurance payments due to job loss. The study was conducted with 582 office workers. As a result of the study, it was revealed that 55.1% of the participants had back pain and 5% of the participants had back pain, and the rate of women in low back pain was higher.

Keel Start MSK Tool is a tool that provides patients with an appropriate treatment approach, minimizes harm and maximizes treatment benefit. Keele Start MSK Tool msk has been successfully developed for primary care in patients, and it categorizes patients by scoring 9 items and categorizing them into subgroups. This tool is a validated prognostic tool (Keele STarT MSK) with established cut-off points to stratify patients with the five most common musculoskeletal (back, neck, knee, shoulder, multiple painful areas) pain into low, intermediate, and high-risk subgroups. provides 108 patients with low back pain were included in the French version of the Keele STarT Low Back Screening Tool (SBST).

In the UK, which started in 2014, with 1200 patients on MSC pain, stratified; No significant change was achieved as a result of this study, which aims to investigate clinical and cost-effectiveness, as well as to reduce clinician's treatment variability and improve patient outcomes (quality of life, physical function, etc.) since the study has not been completed yet.

In another study, general practitioners screened 3063 patients (1591 interventions, 1472 controls). The EMR template included 1237 eligible patients (513 interventions, 724 controls), while 524 consented to data collection (231 interventions, 293 controls). Although the target of participation was 12 weeks, it took 28 weeks. The target for follow-up was 75% and above and a follow-up rate of over 90% was achieved. As a result of this study, the applicability of the randomized controlled trial design was found to be successful. In addition, the accuracy rate of matched treatment options was also high.

In another UK study, 8 general examinations were randomized (4' stratified care, 4 as regular care) and patients had CNS pain in one of the 5 most common sites. A baseline questionnaire was obtained from the patients, and >90% of these 524 patients were followed up for 8 months. Audio recording or video was taken during the examination. Some patients stated that they wanted to clarify the questions asked, but they could not express themselves well because they had to answer only "yes" or "no" because of this scale. The opinion of the doctors, on the other hand, stated that the result of the Keel Start MSK Tool scale and the treatment approach provided them clinically guiding and different perspectives.

Inclusion Criteria:

• The patient must be 18 years or older.
• The location of MSC pain must be one of the 5 regions. These 5 regions; knee, shoulder, back, neck, multi-region.
• Volunteering to participate in the study
• The patient's pain must be chronic. chronic pain; If there is general agreement on the definition of pain today, the recognition of pain as a disease is controversial. Depending on their duration, different types of pain are now classified as chronic pain, and the generally accepted definition is "pain that continues after a normal recovery period."
• The patient's Mini mental test score must be 23 and above. The mini mental state examination is scored on a scale of 0-30 with >25 points interpreted as normal cognitive status.

Exclusion Criteria:

• Those with serious pathological symptoms
• Joint infection
• Cancer
• Rheumatoid arthritis
• Spondyloarthropathy
• Polymyalgia
• Inflammatory arthropathy
• Crystal disease
• Gout
• Those with severe and persistent mental health problems
• Having a diagnosis of dementia
• Those with a terminal illness diagnosis
• Those who have recently experienced trauma or bereavement
• Those who cannot communicate in Turkish
• Those with neurological problems
• Suspected fracture
• Those with joint inflammation
• Those with neuromuscular disease
• Those with systemic disease